Vitamin D deficiency: skeletal and non-skeletal disorders and its treatment with alfacalcidol

Cover Page

Cite item

Full Text

Abstract

The article presents data on physiological role of vitamin D and primary causes of its deficiency. Aspects of native and active vitamin D forms metabolism including its dependence on age and comorbid conditions are discussed. Primary indications for active vitamin D metabolites prescription are described. It is noted that compared with native vitamin D alfacalcidol demonstrates better clinical effectiveness in different types of osteoporosis treatment due to the absence of its metabolism in kidneys and the safety profiles of the medications are similar. Unlike native vitamin D alfacalcidol monotherapy is included in clinical recommendations for this disorder treatment as it demonstrated better effectiveness in bone mineral density increase, risk of falls and fractures reduction, as well as significant relief of pain syndrome. Broad opportunities of Alpha D3-Teva® individual dosage (alfacalcidol) allow to minimize risk of adverse effects development that together with new fractures prevention, pain syndrome reduction and motor activity improvement results in quality of life of patients of all ages improvement.

About the authors

I. S Dydykina

V.A.Nasonova Research Institute of Rheumatology

Email: dydykina_is@mail.ru
115522, Russian Federation, Moscow, Kashirskoe sh., d. 34A

P. S Kovalenko

V.A.Nasonova Research Institute of Rheumatology

канд. мед. наук, мл. науч. сотр. отд. метаболических заболеваний костей и суставов с центром профилактики остеопороза 115522, Russian Federation, Moscow, Kashirskoe sh., d. 34A

A. A Kovalenko

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

глав. врач санатория «Звенигород» 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

References

  1. Спиричев В.Б. Витамины, витаминоподобные и минеральные вещества. Справочник. М.: МЦФЭР, 2004.
  2. Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е. и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы эндокринологии. 2016; 62 (4): 60-84.
  3. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008; 88: 582S-6S.
  4. Беневоленская Л.И., Лесняк О.М. Остеопороз. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2009. / Benevolenskaya L.I., Lesnyak O.M. Osteoporoz. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2009. [in Russian]
  5. Громова О.А., Торшин И.Ю. Витамин Д - смена парадигмы. Под ред. Е.И.Гусева, И.Н.Захаровой. М.: ГЭОТАР-Медиа, 2017
  6. Зоткин Е.Г., Шварц Г.Я. Возможности клинического применения витамина D и его активных метаболитов. Эффективная фармакотерапия. 2013; 38: 50-9.
  7. Беневоленская Л.И., Лесняк О.М. Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. М: ГЭОТАР-Медиа, 2005; с. 146-63.
  8. Holick M.F. Vitamin D status: Measurement, interpretation and clinical application. Ann Epidemiol 2009; 19 (2): 73-8.
  9. Kumar J, Muntner P, Kaskel F.J, Hailpern S.M. MLM prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics 2009; 124: 362-70.
  10. Lee J, Smith J.R, Philipp B.L et al. Vitamin D deficiency in a healthy group of mothers and newborn infants. Clin Pediatr (Phila) 2007; 46: 42-4.
  11. Захарова И.Н., Мальцев С.В., Боровик Т.Э. и др. Недостаточность витамина D у детей раннего возраста в России (результаты многоцентрового исследования - зима 2013-2014 гг.). Педиатрия. 2014; 93 (2): 75-80
  12. Van der Wielen R.P, Löwik M.R, van den Berg H et al. Serum Vitamin D concentrations among elderly people in Europe. Lancet 1995; 346 (8969): 207-10.
  13. Holik M.F. Vitamin D deficiency. New Engl J Med 2007; 357: 266-81.
  14. Kulie T, Groff A, Redmer J et al. Vitamin D. An evidence-based review. J Am Board Family Med 2009; 22 (6): 698-706.
  15. Holick M.F, Binkley N.C, Bischoff-Ferrari H.A et al. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96 (7): 1911-30. doi: 10.1210/jc.2011-0385
  16. Henderson L, Irving K, Gregori J et al. The National Diet and Nutrition Survey: Adults aged 19-64 years. Vol. 3: Vitamin and mineral intake and urinary analysis. The Stationery Office. London, 2003.
  17. Snellman G.L, Byberg L, Lemming E.W et al. Long-term dietary vitamin D intake and risk of fracture and osteoporosis: a longitudinal cohort study of Swedish middle-aged and elderly women. J Clin Endocrinol Metab 2014; 99 (3): 781-90.
  18. Hwang Y.C, Ahn H.Y, Jeong I.K et al. Optimal serum concentration of 25-hydroxivitamin D for bone health in older Korean adults. Caicified Tissue Int 2013; 92 (1): 68-74.
  19. Chernichow S, Fan T, Nocea G, Sen S.S. Calcium and vitamin D intake by postmenopausal women with osteoporosis in France. Curr Med Res Opin 2010; 26 (7): 1667-74.
  20. Ardawi M.S, Sibiany A.M, Bakhsh T.M et al. High prevalence of vitamin D deficiency among healthy Saudi Arabien men: Relationship to bone mineral density, parathyroid hormone, bone turnover markers, and lifestyle factors. Osteoporos Int 2012; 23 (2): 675-86.
  21. Murad M.H, Elamin K.B, Abu Elnour N.O et al. The effect of vitamin D on falls. A systematic review and metaanalysis. J Clin Endocrinol Metab 2011; 96 (10): 2997-3006.
  22. Bischoff-Ferrari H.A, Dawson-Hughes B, Staehelin H.B et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009; 339: b3692. doi: 10.1136/bmj.b3692
  23. Dukas L, Bischoff H.A., Lindpaintner L.S et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004; 52: 230-6.
  24. Pittas A.G, Lau J, Hu F.B, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92 (6): 2017-29.
  25. De Boer I.H, Tinker L.F, Connelly S et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 2008; 31 (4): 701-7.
  26. Pittas A.G, Chung M, Trikalinos T et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med 2010; 152 (5): 307-14.
  27. Giovannucci E, Liu Y, Hollis B.W, Rimm E.B. 25OHD and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008; 168 (11): 1174-80.
  28. Marniemi J, Alanen E, Impivaara O et al. Dietary and serum vitamins and minerals as predictors of myocardial infarction and stroke in elderly subjects. Nutr Metab Cardiovasc Dis 2005; 15 (3): 188-97.
  29. Elamin M.B, Abu Elnour N.O, Elamin K.B et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96 (7): 1931-42.
  30. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Inern Med 2007; 167 (16): 1730-7.
  31. Rejnmark L, Avenell A, Masud T et al. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J Clin Endocrinol Metab 2012; 97 (8): 2670-81.
  32. Dobnig H, Pilz S, Scharnagl H et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all cause and cardiovascular mortality. Arch Intern Med 2008; 168 (12): 1340-9.
  33. Johansson H, Oden A, Kanis J et al. Low serum vitamin D is associate with increased mortality in elderly men: MrOS Sweeden. Osteoporos Int 2012; 23 (3): 991-9.
  34. Шварц Г.Я. Дефицит витамина D и его фармакологическая коррекция. РМЖ. 2009; 17 (7): 477-86.
  35. Шварц Г.Я. Типы дефицита витамина D и их фармакологическая коррекция. Лекарственные средства. Прикладная фармакология и персонализированная фармакотерапия. 2011; 2 (3): 33-42
  36. Шварц Г.Я. Витамин D и D-гормон. М.: Анахарсис, 2005.
  37. Richy F, Dukas L, Schacht E. Differential effects of D-Hormone analogs and native vitamin D on the risk of falls: a comparative meta-analysis. Calcific Tissue Int 2008; 82: 102-7.
  38. Richy F, Schacht E, Bruyere O et al. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures - a comparative meta-analysis. Calcif Tissue Int 2005; 76 (3): 176-86.
  39. Ringe J.D, Dorst A, Faber H et al. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 2004; 24: 63-70.
  40. Orimo H. Akt Rheumatol 1994; 19 (Suppl.): 27-30.
  41. Bischoff-Ferrari H.A, Shao A, Dawson-Hughes B et al. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int 2010; 21(7): 1121-32.
  42. Лесняк О.М. Эффективность и безопасность альфакальцидола в лечении остеопороза и предупреждении переломов: обзор современных данных. Эффективная фармакотерапия. Ревматология, травматология и ортопедия. 2014; 10 (1): 16-22
  43. Richy F, Ethgen O, Bruyere O, Reginster J.Y. Efficacy of alfacalcidol and calcitriol in primary and corticoid-induced osteoporosis: meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004; 15 (4): 301-10.
  44. Del Valle E, Negri A.L, Fradinger E et al. Weekly high-dose ergocalciferol to correct vitamin D deficiency/insufficiency in hemodialysis patients: A pilot trial. Hemodial Int 2014. doi: 10.1111/hdi.12209
  45. Mager D.R, Jackson S.T, Hoffmann M.R et al. Vitamin D supplementation and bone health in adults with diabetic nephropathy: the protocol for a randomized controlled trial. BMC Endocr Dis 2014; 14: 66. doi: 10.1186/1472-6823-14-66

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies